Drug Trial Radar · NCT02525692
Oral ONC201 in Adult Recurrent Glioblastoma
Last checked: Nov 19, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
84
Actual
Start
Jan 2016
Primary completion
Apr 17, 2023
Study completion Apr 17, 2023
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- Oncoceutics, Inc.
- First posted
- Aug 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 2, open-label, 6-arm, multi-center study of dordaviprone (ONC201) in patients with recurrent glioblastoma (Arms A, B, and C), H3 K27M-mutant diffuse glioma (Arm D), or diffuse midline glioma (Arms E and F). The primary objective of this study was the assessment of dordaivprone (ONC201) anti-tumor activity through progression-free survival at 6 months using Response Assessment in Neuro-Oncology (RANO) criteria for high-grade glioma (HGG).
Conditions
- Glioblastoma
- Diffuse Midline Glioma
- H3 K27M Glioma
- Thalamic Glioma
- Infratentorial Glioma
- Basal Ganglia Glioma
Interventions
Dordaviprone (ONC201)Drug
Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Patients With Probability of Progression-Free Survival at 6 MonthsTime frame: Progression-free survival assessments were conducted 6 months following treatment initiation.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Miami Cancer Institute
Miami, Florida
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.